This review highlights ten “hot topics” in current antiviral research:(i) new nucleoside
derivatives (ie, PSI‐352938) showing high potential as a direct antiviral against hepatitis C …

The ten stories told here deal with (i) ribavirin as an inhibitor of IMP dehydrogenase and (ii)
ribavirin, in combination with pegylated interferon, as the present “standard of care” for …

This review article presents the fifth part (part E) in the series of stories on antiviral drug
discovery. The ten stories belonging to this fifth part are dealing with (i) aurintricarboxylic …

This review article that complements the previous review article on “The discovery of
antiviral agents: ten different compounds, ten different stories” presents ten more …

This review article presents the fourth part (part D) in the series of stories on antiviral drug
discovery. The stories told in part D focus on:(i) the cyclotriazadisulfonamide compounds;(ii) …

Three decades of antiviral drugs | Nature Reviews Drug Discovery Skip to main content Thank
you for visiting nature.com. You are using a browser version with limited support for CSS. To …

Abstract 2017 marked the 30th anniversary of the approval of zidovudine (AZT) as the first
HIV/AIDS therapy. Since then, more than eighty antiviral drugs have received FDA approval …

The successful development of antiviral drugs is highly dependent on a close interaction
and collaboration between the chemist and the biologist (biomedic). This is illustrated by a …

I entered the Rega Institute for Medical Research in August 1964, as a medical student, to
start working under the guidance of Prof. Piet De Somer, then professor of microbiology at …

Antivirals become a broader enterprise | Nature Biotechnology Skip to main content Thank you
for visiting nature.com. You are using a browser version with limited support for CSS. To obtain …